Intracranial Hemorrhage in the TST Trial
Ezetimibe
Stroke
DOI:
10.1161/strokeaha.121.035846
Publication Date:
2021-12-29T10:00:51Z
AUTHORS (299)
ABSTRACT
Background and Purpose: Although statins are effective in secondary prevention of ischemic stroke, they also associated with an increase risk intracranial hemorrhage (ICH) certain conditions. In the TST trial (Treat Stroke to Target), we prespecified exploration predictors incident ICH. Methods: Patients stroke previous 3 months or transient attack within 15 days evidence cerebrovascular coronary artery atherosclerosis were randomly assigned a 1:1 ratio target LDL (low-density lipoprotein) cholesterol <70 mg/dL 100±10 mg/dL, using statin ezetimibe. Results: Among 2860 patients enrolled, 31 ICH occurred over median follow-up years (18 13 lower higher group, 3.21/1000 patient-years [95% CI, 2.38–4.04] 2.32/1000 1.61–3.03], respectively). While there no baseline ICH, uncontrolled hypertension (HR, 2.51 1.01–6.31], P =0.041) being on anticoagulant 2.36 1.00–5.62], =0.047)] during significant predictors. On-treatment low was not predictor Conclusions: Targeting compared atherosclerotic nonsignificantly increased Incident ICHs cholesterol. Uncontrolled therapy which has important clinical implications. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01252875; EUDRACT 2009-A01280-57.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (16)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....